Olympus has launched highly sensitive and precise prostate-specific antigen (PSA) and free PSA (fPSA) assays for the Olympus AU3000i immunoassay analyser. The use of PSA and fPSA is well established in the screening and management of prostate cancer, and the PSA assay has a functional sensitivity of 0.015 ìg/L.
The primary tumour marker panel includes AFP, CEA, PSA, and fPSA – assays that account for approximately 70% of the tumour marker workload performed in a laboratory. Additionally, Olympus offers the specialist tumour markers GI-TC and BR-TC, and further tumour markers are planned for the future.
www.olympus.co.uk/diagnostics